BERKELEY, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced new preclinical data ...
In vivo platform enables efficient, site-specific CAR gene insertion under control of an endogenous T cell promoter, producing functional CAR T cells inside the body Single dose administration in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback